Skip to main content
SpringerLink
Log in

Pharmacokinetic and Pharmacodynamic Considerations in Elderly Population

  • Chapter
  • First Online:
Developing Drug Products in an Aging Society

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 26))

Abstract

Physiological changes with age may alter absorption, distribution, metabolism, and excretion of drugs in the elderly population. Reduced elimination and prolonged half-life are most commonly observed pharmacokinetic changes in older patients whereas altered sensitivity to drugs and change in receptor affinity are major pharmacodynamic changes. These potential changes should be considered in designing dosage regimen to elderly population during clinical and pharmaceutical development as well as prescription. Understanding and managing these age-related pharmacokinetic and pharmacodynamics changes is an important factor for the benefit to risk ratio of a new drug product. The physiological changes affecting pharmacokinetics and Pharmacodynamics of drugs and their clinical implications are discussed here.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. US Department of Health and Human Services. Administration on Aging (AoA). In: U.S. Department of Health and Human Services Administration of Community Living. Washington, DC 2013. Available at http://www.aoa.gov/. Accessed July 2015.

  2. Mattison M. Hospital management of older adults. Available at http://www.uptodate.com/contents/hospital-management-of-older-adults. Accessed July 2015.

  3. Lavan AH, O’Grady J, Gallagher PF. Appropriate prescribing in the elderly: Current perspectives. World J Pharmacol. 2015;4:193–209.

    Google Scholar 

  4. Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet. 1998;35:49–64.

    Article  CAS  PubMed  Google Scholar 

  5. Noble RE. Drug therapy in the elderly. Metab Clin Exp. 2003;52:27–30.

    Article  CAS  PubMed  Google Scholar 

  6. Bender AD. Effect of age on intestinal absorption: implications for drug absorption in the elderly. J Am Geriatr Soc. 1968;16:1331–9.

    Article  CAS  PubMed  Google Scholar 

  7. Buxton ILO, Benet LZ. Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism and elimination. In: Goodman and Gilman’s the pharmacological basis of therapeutics, 12th ed; 2011.

    Google Scholar 

  8. Evans MA, Triggs EJ, Cheung M, et al. Gastric emptying rate in the elderly: implications for drug therapy. J Am Geriatr Soc. 1981;29:201–5.

    Article  CAS  PubMed  Google Scholar 

  9. Bhutto A, Morley JE. The clinical significance of gastrointestinal changes with aging. Current Opin Clin Nutr Metab Care. 2008;11:651–60.

    Article  CAS  Google Scholar 

  10. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38:843–53.

    Article  CAS  PubMed  Google Scholar 

  11. Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metab Clin Exp. 1970;19:653–63.

    Article  CAS  PubMed  Google Scholar 

  12. Shock NW, Watkin DM, Yiengst MJ, et al. Age differences in the water content of the body as related to basal oxygen consumption in males. J Gerontol. 1963;18:1–8.

    Article  CAS  PubMed  Google Scholar 

  13. Herman RJ, Wilkinson GR. Disposition of diazepam in young and elderly subjects after acute and chronic dosing. Br J Clin Pharmacol. 1996;42:147–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Turnheim K. Drug dosage in the elderly. Is it rational? Drugs Aging 1998;13:357–79.

    Google Scholar 

  15. Heuberger J, Schmidt S, Derendorf H. When is protein binding important? J Pharm Sci. 2013;102:3458–67.

    Article  CAS  PubMed  Google Scholar 

  16. Lampon N, Tutor JC. Apparent clearance of valproic acid in elderly epileptic patients: estimation of the confounding effect of albumin concentration. Upsala J Med Sci. 2012;117:41–6.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Shepherd AM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol. 1977;4:315–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Huang Z, Ung T. Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics. Curr Drug Metab. 2013;14:226–38.

    CAS  PubMed  Google Scholar 

  19. Paxton JW. Alpha 1-acid glycoprotein and binding of basic drugs. Methods Find Exp Clin Pharmacol. 1983;5:635–48.

    CAS  PubMed  Google Scholar 

  20. Piafsky KM. Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet. 1980;5:246–62.

    Article  CAS  PubMed  Google Scholar 

  21. Lemmens HJ, Burm AG, Hennis PJ, et al. Influence of age on the pharmacokinetics of alfentanil. Gender dependence. Clin Pharmacokinet. 1990;19:416–22.

    Article  CAS  PubMed  Google Scholar 

  22. Schmucker DL. Age-related changes in liver structure and function: implications for disease? Exp Gerontol. 2005;40:650–9.

    Article  CAS  PubMed  Google Scholar 

  23. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56:163–84.

    Article  CAS  PubMed  Google Scholar 

  24. Le Couteur DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet. 1998;34:359–73.

    Article  PubMed  Google Scholar 

  25. Schmucker DL, Woodhouse KW, Wang RK, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther. 1990;48:365–74.

    Article  CAS  PubMed  Google Scholar 

  26. Schaeffel F, Wilhelm H, Zrenner E. Inter-individual variability in the dynamics of natural accommodation in humans: relation to age and refractive errors. J Physiol. 1993;461:301–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Ohnishi A, Kato M, Kojima J, et al. Differential pharmacokinetics of theophylline in elderly patients. Drugs Aging. 2003;20:71–84.

    Article  CAS  PubMed  Google Scholar 

  28. Ereshefsky L, Tran-Johnson T, Davis CM, LeRoy A. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine–new data and review. Clin Chem. 1988;34:863–80.

    CAS  PubMed  Google Scholar 

  29. Abernethy DR, Greenblatt DJ, Shader RI. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther. 1985;232:183–8.

    CAS  PubMed  Google Scholar 

  30. O’Malley K, Crooks J, Duke E, Stevenson IH. Effect of age and sex on human drug metabolism. Br Med J. 1971;3:607–9.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Robertson DR, Wood ND, Everest H, et al. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol. 1989;28:61–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. ElDesoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther. 2007;14:488–98.

    Article  PubMed  Google Scholar 

  33. Guay DR. Use of oral oxymorphone in the elderly. Consult Pharm J Am Soc Consult Pharm. 2007;22:417–30.

    Article  Google Scholar 

  34. Baschiera F, Chang W, Brunel P, Group AS. Effects of aliskiren- and ramipril-based treatment on central aortic blood pressure in elderly with systolic hypertension: a substudy of AGELESS. Vasc Health Risk Manag 2014;10:389–97.

    Google Scholar 

  35. Meisel S, Shamiss A, Rosenthal T. Clinical pharmacokinetics of ramipril. Clin Pharmacokinet. 1994;26:7–15.

    Article  CAS  PubMed  Google Scholar 

  36. Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41:207–24.

    Article  CAS  PubMed  Google Scholar 

  37. Wood AJ, Vestal RE, Wilkinson GR, et al. Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther. 1979;26:16–20.

    Article  CAS  PubMed  Google Scholar 

  38. Twum-Barima Y, Finnigan T, Habash AI, et al. Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol. 1984;17:595–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc. 2009;120:419–28.

    PubMed  PubMed Central  Google Scholar 

  40. Dutra MC, Uliano EJ, Machado DF, et al. Assessment of kidney function in the elderly: a population-based study. Jornal brasileiro de nefrologia: ‘orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia. 2014;36:297–303.

    Article  Google Scholar 

  41. Chen R, Zou SL, Wang ML, et al. Population pharmacokinetics of digoxin in elderly patients. Eur J Drug Metab Pharmacokinet. 2013;38:115–21.

    Article  PubMed  Google Scholar 

  42. Ingrasciotta Y, Sultana J, Giorgianni F, et al. Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study. PLoS ONE. 2015;10:e0122899.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120(280):e1–7.

    Google Scholar 

  44. Kobayashi R, Tashima Y. Visualization of antigen on nitrocellulose membrane by the oxidative coupling reaction of N, N’-dimethyl-p-phenylenediamine and 4-chloro-1-naphthol. Anal Biochem. 1989;183:9–12.

    Article  CAS  PubMed  Google Scholar 

  45. Lapi F, Azoulay L, Yin H, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Taha A, Lenton RJ, Murdoch PS, Peden NR. Non-oliguric renal failure during treatment with mefenamic acid in elderly patients: a continuing problem. Br Med J (Clin Res Ed). 1985;291:661–2.

    Article  CAS  Google Scholar 

  47. Wagner R, Leicht-Biener U, Mucsi I, Seitz K. Ibuprofen or diclofenac is associated with more severe acute kidney injury in nephropathia epidemica. Scand J Urol Nephrol. 2012;46:65–9.

    Article  CAS  PubMed  Google Scholar 

  48. Corsonello A, Pedone C, Corica F, et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med. 2005;165:790–5.

    Article  PubMed  Google Scholar 

  49. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.

    Article  CAS  PubMed  Google Scholar 

  50. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461–70.

    Article  CAS  PubMed  Google Scholar 

  51. Yuen GJ. Altered pharmacokinetics in the elderly. Clin Geriatr Med. 1990;6:257–67.

    CAS  PubMed  Google Scholar 

  52. Weiland NG, Cohen IR, Wise PM. Age-associated alterations in catecholaminergic concentrations, neuronal activity, and alpha 1 receptor densities in female rats. Neurobiol Aging. 1989;10:323–9.

    Article  CAS  PubMed  Google Scholar 

  53. Larson EB, Kukull WA, Buchner D, Reifler BV. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med. 1987;107:169–73.

    Article  CAS  PubMed  Google Scholar 

  54. McGarry K, Laher M, Fitzgerald D, et al. Baroreflex function in elderly hypertensives. Hypertension. 1983;5:763–6.

    Article  CAS  PubMed  Google Scholar 

  55. El-Sharkawy AM, Sahota O, Maughan RJ, Lobo DN. The pathophysiology of fluid and electrolyte balance in the older adult surgical patient. Clin Nutr. 2014;33:6–13.

    Article  CAS  PubMed  Google Scholar 

  56. Lippa AS, Pelham RW, Beer B, et al. Brain cholinergic dysfunction and memory in aged rats. Neurobiol Aging. 1980;1:13–9.

    Article  CAS  PubMed  Google Scholar 

  57. Morley JE, Flood JF, Silver AJ. Opioid peptides and aging. Ann N Y Acad Sci. 1990;579:123–32.

    Article  CAS  PubMed  Google Scholar 

  58. Williams TJ, Mitterling KL, Thompson LI, et al. Age- and hormone-regulation of opioid peptides and synaptic proteins in the rat dorsal hippocampal formation. Brain Res. 2011;1379:71–85.

    Article  CAS  PubMed  Google Scholar 

  59. Lindeman RD, Lee TD Jr, Yiengst MJ, Shock NW. Influence of age, renal disease, hypertension, diuretics, and calcium on the antidiuretic responses to suboptimal infusions of vasopressin. J Lab Clin Med. 1966;68:206–23.

    CAS  PubMed  Google Scholar 

  60. Albrecht S, Ihmsen H, Hering W, et al. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther. 1999;65:630–9.

    Article  CAS  PubMed  Google Scholar 

  61. Morrill AM, Ge D, Willett KC. Dosing of target-specific oral anticoagulants in special populations. Ann Pharmacother. 2015;49:1031–45.

    Article  CAS  PubMed  Google Scholar 

  62. Tinetti ME, Han L, Lee DS, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014;174:588–95.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Rajman I. PK/PD modelling and simulations: utility in drug development. Drug Discov Today. 2008;13:341–6.

    Article  CAS  PubMed  Google Scholar 

  64. Chien JY, Friedrich S, Heathman MA, et al. Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J. 2005;7:E544–59.

    Article  PubMed  PubMed Central  Google Scholar 

  65. De Cock RF, Piana C, Krekels EH, et al. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67(Suppl 1):5–16.

    Article  PubMed  Google Scholar 

  66. Committee for Human Medicinal Products, European Medicines Agency. Adequacy of guidance on the elderly regarding medicinal products for human use. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500049541.pdf. Accessed July 2015.

  67. Cerreta F, Eichler HG, Rasi G. Drug policy for an aging population—the European Medicines Agency’s geriatric medicines strategy. New Engl J Med. 2012;367:1972–4.

    Article  CAS  PubMed  Google Scholar 

  68. Saeed MA, Vlasakakis G, Della Pasqua O. Rational use of medicines in older adults: can we do better during clinical development? Clin Pharmacol Ther. 2015;97:440–3.

    Article  CAS  PubMed  Google Scholar 

  69. Mano Y, Sugiyama Y, Ito K. Use of a physiologically based pharmacokinetic model for quantitative prediction of drug-drug interactions via CYP3A4 and estimation of the intestinal availability of CYP3A4 substrates. J Pharm Sci. 2015;104:3183–93.

    Article  CAS  PubMed  Google Scholar 

  70. Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometr Syst Pharmacol 2013;2:e63.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, 32610-0494, USA

    Jatinder Kaur Mukker, Ravi Shankar Prasad Singh & Hartmut Derendorf

Authors
  1. Jatinder Kaur Mukker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ravi Shankar Prasad Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hartmut Derendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hartmut Derendorf .

Editor information

Editors and Affiliations

  1. Graz University of Technology, Graz, Austria

    Sven Stegemann

Rights and permissions

Reprints and permissions

Copyright information

© 2016 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Mukker, J.K., Singh, R.S.P., Derendorf, H. (2016). Pharmacokinetic and Pharmacodynamic Considerations in Elderly Population. In: Stegemann, S. (eds) Developing Drug Products in an Aging Society. AAPS Advances in the Pharmaceutical Sciences Series, vol 26. Springer, Cham. https://doi.org/10.1007/978-3-319-43099-7_10

Download citation

Publish with us

Policies and ethics

Search

Navigation